Form 4: Cytek Biosciences SVP Vests RSUs, Sells Shares for Tax
Insider Transaction Report
Philippe Busque, SVP of Global Sales and Services at Cytek Biosciences, reported the vesting of Restricted Stock Units and subsequent sale of shares to cover tax obligations.
Summary
- Philippe Busque, SVP, Global Sales and Services, acquired a total of 7,371 shares of Cytek Biosciences Common Stock through the vesting of Restricted Stock Units (RSUs) on November 18, 2025.
- Concurrently, Busque disposed of 1,885 shares of Common Stock at a price of $5.53 per share to satisfy tax withholding obligations related to the RSU vesting.
- Following these transactions, Busque directly beneficially owns 28,902 shares of Common Stock.
- Remaining derivative securities (RSUs) beneficially owned total 8,714, 20,628, and 48,338 units, with various vesting schedules extending into 2026.
Sentiment
Score: 5
Explanation: The filing reports routine executive compensation events (RSU vesting and tax-related sales), which are neutral in sentiment. There are no unexpected positive or negative financial outcomes for the company or the executive beyond the standard compensation structure.
Positives
- Vesting of Restricted Stock Units indicates continued compensation and retention of a key executive.
- The executive retains a significant number of shares (28,902 common shares) after tax-related sales, demonstrating ongoing equity interest.
Negatives
- The sale of 1,885 shares, while for tax purposes, represents a reduction in the executive's direct holdings.
Future Outlook
The filing details future vesting schedules for Restricted Stock Units extending into 2026, indicating ongoing executive compensation and retention plans.
Industry Context
This Form 4 filing reflects a routine executive compensation event, common across publicly traded companies, where Restricted Stock Units vest and a portion of shares are sold to cover tax liabilities. It does not provide broader industry insights but confirms the company's standard practice for executive equity incentives.
Stakeholder Impact
- Shareholders: Minor dilution from RSU vesting, but also a sign of executive retention and alignment of interests. The tax-related sale is a routine event.
- Employees: Reflects the company's executive compensation structure, which may influence broader employee incentive programs.
Next Steps
- Future vesting of remaining Restricted Stock Units on various dates in 2024, 2025, and 2026.
Key Dates
| Date | Description |
|---|---|
| May 18, 2024 | First vesting date for a portion of RSU Award (13/48 of total shares for one award, 2/48 for another). |
| August 18, 2024 | Vesting date for a portion of RSU Awards (3/48 of total shares for multiple awards). |
| November 18, 2024 | Vesting date for a portion of RSU Awards (3/48 of total shares for multiple awards). |
| March 10, 2025 | Vesting date for a portion of RSU Awards (4/48 of total shares for multiple awards). |
| May 18, 2025 | Vesting date for a portion of RSU Awards (2/48 of total shares for multiple awards). |
| November 18, 2025 | Transaction date for RSU vesting and tax-related share dispositions. |
| November 20, 2025 | Date the Form 4 was signed by the attorney-in-fact. |
| March 10, 2026 | Vesting date for a portion of RSU Award (4/48 of total shares for one award), until fully vested. |
Keywords
Cytek Biosciences, CTKB, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Executive Compensation, Philippe Busque, Share Sale, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.